<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <p class="gem-c-title__context">
      Guidance
    </p>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Completed Paediatric Studies - submission, processing and assessment in a no-deal Brexit
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">Guidance on the submission, processing and assessment of all completed paediatric studies sponsored by Marketing Authorisation Holders (MAHs) in a no-deal Brexit.</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 11 March 2019
    <br></br>Last updated 9 October 2019
      — <a href="#history" class="app-c-published-dates__history-link govuk-link">see all updates</a>
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>




<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav class="gem-c-contents-list  gem-c-contents-list--no-underline " role="navigation" data-module="track-click">
      <h2 class="gem-c-contents-list__title">Contents</h2>

    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#legal-background-and-scope" data-track-options="{"dimension29":"Legal background and scope"}" href="#legal-background-and-scope">Legal background and scope</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#submission-of-information" data-track-options="{"dimension29":"1. Submission of information"}" href="#submission-of-information">1. Submission of information</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#initial-appraisal" data-track-options="{"dimension29":"2. Initial appraisal"}" href="#initial-appraisal">2. Initial appraisal</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 4" data-track-label="#transitional-provisions" data-track-options="{"dimension29":"3. Transitional provisions"}" href="#transitional-provisions">3. Transitional provisions</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 5" data-track-label="#workflow-steps-for-submission-and-assessment-of-mah-sponsored-paediatric-studies" data-track-options="{"dimension29":"Workflow steps for submission and assessment of MAH sponsored paediatric studies"}" href="#workflow-steps-for-submission-and-assessment-of-mah-sponsored-paediatric-studies">Workflow steps for submission and assessment of MAH sponsored paediatric studies</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 6" data-track-label="#processing-and-assessment-of-outcome-of-eu-article-45-work-sharing-procedures" data-track-options="{"dimension29":"Processing and assessment of outcome of EU Article 45 work sharing procedures"}" href="#processing-and-assessment-of-outcome-of-eu-article-45-work-sharing-procedures">Processing and assessment of outcome of EU Article 45 work sharing procedures</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 7" data-track-label="#contact-mhra" data-track-options="{"dimension29":"Contact MHRA\n"}" href="#contact-mhra">Contact MHRA
</a>

        </li>
    </ol>
</nav>
      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<div class="call-to-action">
<h3 id="stay-up-to-date">Stay up to date</h3>

<p>Get ready for Brexit on 31 October 2019. This page tells you how to prepare for Brexit. It will be updated if anything changes, including if a deal is agreed.</p>

<p><a href="https://www.gov.uk/email-signup/?topic=/government/brexit">Sign up to email alerts</a> to get the latest information</p>
</div>

<p>This guidance will apply from exit day in line with the <a rel="external" href="http://www.legislation.gov.uk/uksi/2019/775/contents/made">Human Medicines Regulations (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019</a>.</p>

<h2 id="legal-background-and-scope">Legal background and scope</h2>

<p><a rel="external" href="http://www.legislation.gov.uk/ukdsi/2019/9780111179185/part/5?view=plain">Regulation 78A(13) and (14) of the Human Medicines Regulations 2012, as amended by the Human Medicines (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019</a>, requires that holders of a UK marketing authorisation who sponsor a study which involves use in the paediatric population in respect of the medicinal product to which that authorisation relates must submit to the Medicines and Healthcare products Regulatory Agency (<abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>) results of the study within the period of six months beginning with the day on which the trial ended.</p>

<p>This applies irrespective of whether or not:</p>

<ul>
  <li>
    <p>the studies are conducted in accordance with an agreed paediatric investigation plan (<abbr title="paediatric investigation plan">PIP</abbr>); or</p>
  </li>
  <li>
    <p>the <abbr title="Marketing Authorisation Holder">MAH</abbr> intends to apply for a marketing authorisation for a paediatric indication in relation to the product.</p>
  </li>
</ul>

<p>These provisions replace Article 46 of Regulation (EC) No 1901/2006 (the ‘Paediatric Regulation’).</p>

<p><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will also consider the outcome of <abbr title="Coordination Group for Mutual Recognition and Decentralised Procedures - Human">CMDh</abbr> paediatric work-sharing procedures (<abbr title="paediatric work-sharing procedures">PdWS</abbr>) reviewed under Article 45 of Regulation (EC) No 1901/2006 (as amended). If required, <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will request updates to the product information (<abbr title="product information">PI</abbr>) for UK Marketing Authorisations.</p>

<h2 id="submission-of-information">1. Submission of information</h2>

<p>The <abbr title="Marketing Authorisation Holder">MAH</abbr> needs to submit a cover letter <a rel="external" href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/785033/Annex_I_-_Suggested_MAH_cover_letter_template.docx">(suggested cover letter template)</a> (MS Word Document, 29.3KB) within 6 months of completion (i.e. date of last visit of last subject undergoing the trial, unless otherwise justified in the protocol) of the concerned paediatric studies to the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> in eCTD format to this mailbox: <a href="mailto:paediatricstudies@mhra.gov.uk">paediatricstudies@mhra.gov.uk</a>.</p>

<p>The <abbr title="Marketing Authorisation Holder">MAH</abbr> should indicate in the cover letter whether the study(ies):</p>

<p>1.1. are linked to other paediatric studies which have been or will be the subject of other submissions under <a rel="external" href="http://www.legislation.gov.uk/ukdsi/2019/9780111179185/part/5?view=plain">Regulation 78A of the Human Medicines Regulations 2012, as amended by the Human Medicines (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019</a>.</p>

<p>If this is the case, the <abbr title="Marketing Authorisation Holder">MAH</abbr> should provide the study title(s) with approximate date of completion. If the study(ies) relate to a UK <abbr title="paediatric investigation plan">PIP</abbr>, the <abbr title="Marketing Authorisation Holder">MAH</abbr> should provide the <abbr title="paediatric investigation plan">PIP</abbr> number.</p>

<p>1.2. have been or will be submitted in the UK as part of a variation/extension or any other application including this paediatric study. If this is the case, the <abbr title="Marketing Authorisation Holder">MAH</abbr> should:</p>

<ul>
  <li>
    <p>specify the UK procedure number, if available or the type of application this will be submitted under</p>
  </li>
  <li>
    <p>confirm that the application will be submitted within the next 6 months</p>
  </li>
  <li>
    <p>confirm that, based on the results of the study, no urgent safety update of the product information is required</p>
  </li>
</ul>

<p><abbr title="Marketing Authorisation Holder">MAH</abbr> should provide any relevant information about any related Article 46 of Regulation (EC) No 1901/2006 procedure(s) or <abbr title="European Union">EU</abbr> agreed <abbr title="paediatric investigation plan">PIP</abbr>(s).</p>

<p>The <abbr title="Marketing Authorisation Holders">MAHs</abbr> should also state whether as a result of the paediatric study there is a need to update the product information.</p>

<h2 id="initial-appraisal">2. Initial appraisal</h2>

<p>On receipt of the cover letter, <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will carry out an initial appraisal of whether an assessment procedure is required at this stage. One of the following may apply:</p>

<p>2.1. Assessment of the data is not required at this stage and <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will maintain records including justification for the decision, e.g. that a regulatory submission to vary the Marketing Authorisation is planned in the next 6 months, or any other agreed reason(s) to defer the procedure.</p>

<p>2.2. Limited evaluation of the study data may be undertaken if the <abbr title="Marketing Authorisation Holder">MAH</abbr> provides robust justification that the study data are unlikely to warrant product information (<abbr title="product information">PI</abbr>) changes. The <abbr title="Marketing Authorisation Holder">MAH</abbr> will need to state in the cover letter that one or more of the following criteria are met:</p>

<ul>
  <li>the same data have been reviewed in another regulatory procedure by <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> or another competent authority and the review has not led to <abbr title="product information">PI</abbr> changes</li>
  <li>the study was conducted mainly in adult patients with limited paediatric patients included</li>
  <li>the drug is already licensed in the paediatric study population and the study does not provide new <abbr title="Pharmacokinetic">PK</abbr>, efficacy or safety data</li>
  <li>the study, due to its design, limited number of paediatric patients, discontinuation or other reason does not allow conclusions on efficacy or safety that would impact on the drug’s benefit:risk ratio or be useful to prescribers and patients</li>
  <li>only interim results from an ongoing study are available which will be assessed later in their totality</li>
  <li>the study has been conducted in populations and/or diseases that are not applicable to UK (for example hay fever to specific seasonal pollen found in non-UK countries)</li>
  <li>other justification as to why a detailed assessment is not required at this stage</li>
</ul>

<p>If one or more of the above criteria are met, the <abbr title="Marketing Authorisation Holder">MAH</abbr> should submit the study report and a short clinical overview (as in 2.3) including justification why <abbr title="product information">PI</abbr> changes are not necessary. A variation application will not be requested if <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> agrees with the <abbr title="Marketing Authorisation Holder">MAH</abbr>’s justification not to update the <abbr title="product information">PI</abbr>.</p>

<p>2.3. If review of the data is required when the <abbr title="Marketing Authorisation Holder">MAH</abbr> proposes a <abbr title="product information">PI</abbr> update or when <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> concludes after the initial appraisal, that a full assessment is needed to robustly conclude on prospective <abbr title="product information">PI</abbr> updates, <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will notify the <abbr title="Marketing Authorisation Holder">MAH</abbr> to submit the paediatric data within 60 days as a type II variation application (change code C.I.13 - complex type II variations fees will be applicable). The <abbr title="Marketing Authorisation Holder">MAH</abbr> should submit the following:</p>

<ul>
  <li>
    <p>Final clinical study report</p>
  </li>
  <li>
    <p>A short clinical overview clarifying the context of the data, including information on the pharmaceutical formulation used in the study, the existence of a suitable paediatric formulation and if relevant, conditions for an extemporaneous formulation.</p>
  </li>
  <li>
    <p>A summary of Product Characteristics/ Patient Leaflet (<abbr title="Summary of product characteristics">SmPC</abbr>/PL) proposal to update the paediatric information, or when none is considered required, justification that changes are not necessary.</p>
  </li>
  <li>
    <p>For a paediatric study that is part of a development program including a <abbr title="paediatric investigation plan">PIP</abbr>, a line listing of all relevant studies.</p>
  </li>
  <li>
    <p>If the <abbr title="Marketing Authorisation Holder">MAH</abbr> holds other paediatric studies for the same active substance falling under the scope of <abbr title="European Union">EU</abbr> Article 45 of Regulation (EC) No 1901/2006 which have not yet been assessed by a competent authority, these should be submitted along with a clinical overview clarifying the context of the data.</p>
  </li>
</ul>

<p>If the <abbr title="Marketing Authorisation Holder">MAH</abbr> is unable to submit the type II variation within the 60-day timeframe, they must justify the delay and propose a new submission date.</p>

<h2 id="transitional-provisions">3. Transitional provisions</h2>

<p>If the results of a paediatric study have been submitted to <abbr title="European Medicines Agency">EMA</abbr> or <abbr title="Coordination Group for Mutual Recognition and Decentralised Procedures - Human">CMDh</abbr> under Article 46 of Regulation (EC) 1901/2006 prior to exit day, the process will remain within the <abbr title="European Union">EU</abbr> assessment framework and no UK equivalent procedure will be initiated unless the <abbr title="Marketing Authorisation Holder">MAH</abbr> indicates that an urgent safety update of the product information (<abbr title="product information">PI</abbr>) is required.</p>

<p>Upon finalisation of the <abbr title="European Union">EU</abbr> procedure and availability of the final assessment report, <abbr title="Marketing Authorisation Holders">MAHs</abbr> should submit this to <a href="mailto:paediatricstudies@mhra.gov.uk">paediatricstudies@mhra.gov.uk</a>.</p>

<p><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will check the applicability of the outcome of the EUprocedure for UK products. If there are proposed changes to the <abbr title="product information">PI</abbr> which can be directly implemented to relevant UK products, if not already submitted, <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will request <abbr title="Marketing Authorisation Holders">MAHs</abbr> to submit a Type IB variation to update the <abbr title="product information">PI</abbr> within 60 days.</p>

<h2 id="workflow-steps-for-submission-and-assessment-of-mah-sponsored-paediatric-studies">Workflow steps for submission and assessment of <abbr title="Marketing Authorisation Holder">MAH</abbr> sponsored paediatric studies</h2>

<table>
  <thead>
    <tr>
      <th scope="col">Steps</th>
      <th scope="col">Day</th>
      <th scope="col">Action</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>1</td>
      <td>0</td>
      <td>Receipt of letter notifying <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> of completed study from <abbr title="Marketing Authorisation Holder">MAH</abbr> (see suggested template) via <a href="mailto:paediatricstudies@mhra.gov.uk">paediatricstudies@mhra.gov.uk</a>
</td>
    </tr>
    <tr>
      <td>2</td>
      <td>7</td>
      <td>Allocate procedure to medical assessor</td>
    </tr>
    <tr>
      <td>3</td>
      <td>14</td>
      <td>Inform <abbr title="Marketing Authorisation Holder">MAH</abbr> whether assessment of the data is required: A). If required, a variation is requested within 60 days, details of a submission package is described in section 2.2 of Submission of information, go to step 4, B). If an <abbr title="European Medicines Agency">EMA</abbr> P46 or <abbr title="Coordination Group for Mutual Recognition and Decentralised Procedures - Human">CMDh</abbr> <abbr title="paediatric work-sharing procedures">PdWS</abbr> under Article 46 of Reg.1901/2006 has been completed prior exit day and <abbr title="product information">PI</abbr> changes is a direct implementation to relevant UK products, step 11, C). If not required, <abbr title="Marketing Authorisation Holder">MAH</abbr> will be informed that no further action is needed</td>
    </tr>
    <tr>
      <td>4</td>
      <td>-14</td>
      <td>
<abbr title="Marketing Authorisation Holder">MAH</abbr> submits data as variation type II, followed by Validation process (up to 14 calendar days)</td>
    </tr>
    <tr>
      <td>5</td>
      <td>Clock starts: 0</td>
      <td>Provide <abbr title="Marketing Authorisation Holder">MAH</abbr> with start date of procedure</td>
    </tr>
    <tr>
      <td>6</td>
      <td>Standard: 59/60 (in exceptional circumstances for Extended: 89/90)</td>
      <td>Preliminary <abbr title="Assessment Report">AR</abbr> followed by clock-stop period if there is a need for <abbr title="Request for Further Information">RFI</abbr> or  Preliminary/Final <abbr title="Assessment Report">AR</abbr>, where changes to the <abbr title="product information">PI</abbr> could be implemented at the end of the procedure if applicable</td>
    </tr>
    <tr>
      <td>7</td>
      <td>Clock-stop</td>
      <td>Clock-stop period should not be longer than 60 days for responses + 60 days for assessment of the responses (extension of clock-stop period could be considered upon request)</td>
    </tr>
    <tr>
      <td>8</td>
      <td>Standard: 60 (Extended: 90)</td>
      <td>Final <abbr title="Assessment Report">AR</abbr> sent to <abbr title="Marketing Authorisation Holder">MAH</abbr>, where changes to the <abbr title="product information">PI</abbr> could be implemented at the end of procedure if applicable</td>
    </tr>
    <tr>
      <td>9</td>
      <td>Standard: 75 (Extended: 105)</td>
      <td>Draft Public paediatric <abbr title="Assessment Report">AR</abbr> sent to <abbr title="Marketing Authorisation Holder">MAH</abbr> to comment on any confidential/commercial sensitive information within 15 days</td>
    </tr>
    <tr>
      <td>10</td>
      <td>Standard: 90 (Extended: 120)</td>
      <td>Publish Public paediatric <abbr title="Assessment Report">AR</abbr> on <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> website</td>
    </tr>
    <tr>
      <td>11</td>
      <td>60</td>
      <td>If step <3b> is applicable, request will be sent to <abbr title="Marketing Authorisation Holders">MAHs</abbr> for type IB variations submission, to update the <abbr title="product information">PI</abbr> within 60 days</td>
    </tr>
  </tbody>
</table>

<h2 id="processing-and-assessment-of-outcome-of-eu-article-45-work-sharing-procedures">Processing and assessment of outcome of <abbr title="European Union">EU</abbr> Article 45 work sharing procedures</h2>

<p><abbr title="Marketing Authorisation Holders">MAHs</abbr> are not required to submit to the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> information on paediatric studies completed by 26 January 2007 and which fall under the remit of Article 45 of Regulation (EC) No 1901/2006 work sharing procedure.</p>

<p><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will monitor the published Public Assessment Reports (<abbr title="Public Assessment Report">PAR</abbr>) of Article 45 <abbr title="paediatric work-sharing procedures">PdWS</abbr> procedures. Once a new <abbr title="Public Assessment Report">PAR</abbr> is identified, any proposed (<abbr title="product information">PI</abbr>) changes and their applicability for UK products with the same active substance will be reviewed.</p>

<ol>
  <li>If products with the same active substance are not available in the UK or the <abbr title="product information">PI</abbr> changes proposed are not applicable to UK products, no further action will be taken.</li>
  <li>If the proposed <abbr title="product information">PI</abbr> changes are directly applicable to UK products, if not already submitted, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will send a request to the UK <abbr title="Marketing Authorisation Holders">MAHs</abbr> to submit a type IB variation within 60 days.</li>
  <li>If proposed <abbr title="product information">PI</abbr> changes are not directly applicable to the UK products, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> may adapt the recommendations and subsequently send requests to UK <abbr title="Marketing Authorisation Holders">MAHs</abbr> for type IB variation, where the UK adapted recommendations will be provided, within 60 days.</li>
  <li>If <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> considers that the <abbr title="Marketing Authorisation Holders">MAHs</abbr> should provide supplementary data in order to conclude on potential <abbr title="product information">PI</abbr> changes for the UK products and further UK assessment is deemed necessary, a type II variation could be requested within 60 days.</li>
</ol>

<h2 id="contact-mhra">Contact <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>
</h2>
<p>Please direct any queries to <a href="mailto:specialpopulationsunit@mhra.gov.uk">specialpopulationsunit@mhra.gov.uk</a>.</p>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates app-c-published-dates--history" id="history" data-module="toggle" lang="en">
    Published 11 March 2019
    <br></br>Last updated 9 October 2019
      <a href="#full-history" class="app-c-published-dates__toggle govuk-link" data-controls="full-history" data-expanded="false" data-toggled-text="- hide all updates">+ show all updates</a>
      <div class="app-c-published-dates__change-history js-hidden" id="full-history">
        <ol>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-10-09T16:11:01.000+01:00">9 October 2019</time>
              Added new information (section 2.2). This covers the criteria Marketing Authorisation Holders will need to meet if only limited evaluation of the study data is to take place. 
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-10-09T12:34:58.000+01:00">9 October 2019</time>
              Change of text within Stay up to date box.
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-08-08T14:51:47.000+01:00">8 August 2019</time>
              Removed some outdated background content.
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-03-11T15:04:00.000+00:00">11 March 2019</time>
              First published.
            </li>
        </ol>
      </div>
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">

    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-1329cd34" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-related_items-1329cd34" data-module="gem-toggle">


  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar  gem-c-related-navigation__section-link--other" data-track-category="relatedLinkClicked" data-track-action="1.1 Related content" data-track-label="/find-eu-exit-guidance-business" data-track-options="{"dimension28":"1","dimension29":"Find Brexit guidance for your business"}" href="/find-eu-exit-guidance-business">Find Brexit guidance for your business</a></li>

  </ul>
</nav>



      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-1329cd34" data-module="gem-toggle">

    <h3 id="related-nav-collections-1329cd34" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="2.1 Collection" data-track-label="/government/collections/mhra-guidance-and-publications-on-a-possible-no-deal-scenario" data-track-options="{"dimension28":"1","dimension29":"MHRA guidance and publications about a possible no-deal Brexit"}" href="/government/collections/mhra-guidance-and-publications-on-a-possible-no-deal-scenario">MHRA guidance and publications about a possible no-deal Brexit</a></li>

  </ul>
</nav>

  </div>


</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-85fbb821" data-module="gem-toggle">

    <h2 id="related-nav-topics-85fbb821" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/vigilance-safety-alerts" data-track-options="{"dimension28":"1","dimension29":"Vigilance, safety alerts and guidance"}" href="/topic/medicines-medical-devices-blood/vigilance-safety-alerts">Vigilance, safety alerts and guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>